top of page

Topic

Interstitial Lung Disease (ILD)

2 Podcasts on BackTable

Hear how experienced physicians manage Interstitial Lung Disease (ILD) on BackTable. Learn from podcasts, cases, and courses curated by physician content creators, covering diagnosis, clinical decision-making, and treatments. Get the BackTable app to follow this Topic and hear more of the conversations that matter to your practice.

Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer
00:00 / 01:04

Save your progress. Continue watching on the BackTable app.

BackTable Tumor Board

Episode # 52  •  24 Mar 2026

Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer

Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful attention to toxicity. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Sara Nunnery review the role of ADCs in HER2-positive disease and their growing application in HER2-low and HER2-ultralow metastatic settings.

More on Interstitial Lung Disease (ILD)

Loading recent podcasts…

Tumor Board

Tumor Board Episode #52

Mar 24, 2026

with Dr. Sara Nunnery, Dr. Kate Baker

Antibody Drug Conjugates Across the HER2 Spectrum: From HER2-Positive to Ultralow Breast Cancer

Antibody-drug conjugates (ADCs) are expanding treatment options in breast cancer, but their use requires careful...

140+ listens

Tumor Board

Tumor Board Episode #48

Feb 17, 2026

with Dr. Erika Hamilton, Dr. Lindsay Peterson

HER2-Positive Metastatic Breast Cancer: Treatment Insights & Protocols

In a patient with metastatic HER2-positive breast cancer, what should guide the next decision: trial data, toxicity, or...

240+ listens

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

bottom of page